In the quest of novel scaffolds for the management of androgen sensitive prostatic disorders like prostate cancer and benign prostatic hyperplasia, a series of twenty-six aryl/heteroaryl piperazine derivatives have been described. Three compounds 8a, 8c and 9a exhibited good activity profile against androgen sensitive prostate cancer cell line (LNCaP) with EC50 values of 9.8, 7.6 and 11.2 µM, respectively. These compounds caused a decrease in luciferase activity and decline in the PSA and Ca2+ levels, which are indicative of its anti-androgenic and α1A-adrenergic receptor blocking activities, respectively. Compound 9a reduced prostatic weights of rat (47%) and in pharmacokinetic analysis at 10 mg/kg it demonstrated an MRT of ~14 h post dose, exhibiting high levels in prostate. Compound 9a docked in a similar orientation as hydroxyflutamide on androgen receptor and showed strong π-π interactions. These findings reveal that compound 9a is a promising candidate for management of prostatic disorders with anti-androgenic and α1A-blocking activities.